#301 - What Actually Moves the Needle on Cardiovascular Risk | Dr. Kevin Maki & Mike Haney
LEVELS – A Whole New LevelShow Notes
High cholesterol. Elevated ApoB. A positive CAC score. Now what?
Most people quickly find themselves trapped between two extremes: simplistic advice to “cut saturated fat” and online influencers insisting cholesterol doesn’t matter at all. In this episode of A Whole New Level, Mike Haney sits down with clinical research scientist Dr. Kevin Maki to cut through the confusion.
Drawing on more than 35 years of cardiovascular research, Maki explains why heart disease risk is about much more than LDL cholesterol alone. He breaks down the roles of inflammation, blood sugar, family history, kidney function, and lipoproteins, while also making a clear case for something many people resist: LDL and ApoB still matter. A lot.
The evidence increasingly suggests that when it comes to atherosclerosis, lower for longer is better. That has important implications for diet, statins, and how early we should intervene.
Mike and Dr. Maki also tackle saturated fat, seed oils, red meat, industry-funded research, and how to separate evidence from online nutrition debates.
Free course: Improve your metabolic health
Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
🎙️ About the Guest: Dr. Kevin Maki is founder and Chief Science Officer of Midwest Biomedical Research and an Adjunct Professor in the School of Public Health at Indiana University. A former president of the National Lipid Association, he has spent more than three decades designing and leading clinical trials focused on cardiovascular disease, diabetes, nutrition, and lipid management.
His research has included studies on cholesterol-lowering therapies, dietary patterns, red meat, seed oils, inflammation, and cardiometabolic risk reduction.
📍What Dr. Kevin Maki & Mike Haney discussed: 0:00 — Dr. Maki’s background in clinical research 4:30 — How industry-funded nutrition research actually works 15:00 — The Framingham Heart Study and the “Big Four” risk factors 20:00 — FLASH-GLICK: the ten factors that drive cardiovascular risk 26:00 — Why inflammation may be the next frontier in prevention 33:00 — LDL, ApoB, and the “lower for longer” principle 42:00 — Particle size, ApoB, and what advanced lipid testing adds 47:00 — Why everyone should know their Lp(a) 51:00 — Saturated fat, seed oils, and the “compared to what?” problem 62:00 — What the red meat evidence actually shows 72:00 — Statins, lifestyle, and LDL treatment goals 82:00 — Why earlier LDL lowering may provide the biggest benefit
🔗 Helpful Links: Watch the conversation: https://youtu.be/l8QzuuTYxLI Beef Consumption and Cardiovascular Disease Risk Factors: A Systematic Review and Meta-analysis of Randomized Controlled Trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC11621491/ Low-Density Lipoprotein Cholesterol Lowering and Risk of Major Adverse Cardiovascular Events in Primary Prevention Trials: A Meta-Analysis: https://www.sciencedirect.com/science/article/pii/S1933287426000395 PREDIMED Trial (Mediterranean Diet & Primary Prevention): https://www.nejm.org/doi/abs/10.1056/NEJMoa1200303 CORDIOPREV Trial: https://pubmed.ncbi.nlm.nih.gov/35525255/ The Framingham Heart Study: A Historical Perspective: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61752-3/abstract Midwest Biomedical Research: https://midwestbiomedicalresearch.com/ National Lipid Association: https://www.lipid.org/
✅ Subscribe here on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.